Accès à distance ? S'identifier sur le proxy UCLouvain
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Primary tabs
- Open access
- 326.29 K
| Document type | Article de périodique (Journal article) – Article de recherche |
|---|---|
| Access type | Accès libre |
| Publication date | 2012 |
| Language | Anglais |
| Journal information | "Lancet" - Vol. 380, no.9856, p. 1829-39 (2012) |
| Peer reviewed | yes |
| issn | 0140-6736 |
| e-issn | 1474-547X |
| Publication status | Publié |
| Affiliation | UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire |
| MESH Subject | Adjuvants, Immunologic ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting ; Peptides ; Recurrence ; Treatment Outcome ; Young Adult ; Administration, Cutaneous ; Adolescent ; Adult ; Antibodies, Monoclonal, Humanized ; Female ; Humans ; Immunosuppressive Agents ; Infusions, Intravenous |
| Links |
| Bibliographic reference | Coles, Alasdair J ; Twyman, Cary L ; Arnold, Douglas L ; Cohen, Jeffrey A ; Confavreux, Christian ; et. al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.. In: Lancet, Vol. 380, no.9856, p. 1829-39 (2012) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/124398 |